79. Complete the actions necessary to expand the product claim originally submitted to and listed by WHO PQ for the use of the professional use product to allow caregivers to test children 24 months and older by end Q1 2019.

80. Develop and execute a study by end Q2 2019 to verify usability in adult caregivers testing children with OraQuick HIV Self-Test.

81. Work with partners to develop and execute a more comprehensive study to assess social consequences of the use of the OraQuick HIV Self-test in testing children by parents or caregivers for consideration by WHO in self-testing guidelines

79. Completed clinical testing for expanding claims for the professional products to children and intend to make WHO submission in May

80. Currently working on usability for expanding claims to children on the self-test. Work will be completed in Q2 and expect to submit to WHO in May


22. Make every effort to stay in the EID market to ensure there is a sufficient testing capacity to reach and maintain accelerated Fast Track targets (95% of HEI tested by 2020 and beyond).

23. Ensure consistent reagent pricing across partners within countries and within regions, and provide a transparent breakdown of pricing for the products and services sold.

24. Consider moving from separate instrument, consumable, and service procurement towards more consolidated, ideally all-inclusive pricing models.

25. Provide service level agreements that clearly spell out key performance indicators POC, near POC, and high-throughput laboratory instruments, including target up-times and failure rate threshold (with consideration for different causes), plus a mitigation plan when the threshold is exceeded.

26. Consider the inclusion of a clinical indeterminate range in test result reports for more accurate diagnosis of infants per WHO guidelines.

27. Rapidly communicate stock shortages with major buyers and work on joint mitigation strategies.